10-Q: Bowen Acquisition Faces Nasdaq Delisting Amid Redemptions

Bowen Acquisition Corp reported a significant decline in its trust account due to high redemptions and received multiple Nasdaq delisting notices, raising substantial doubt about its ability to continue as a going concern.

Summary

• A net loss of $1,289,691 was reported for the six months ended June 30, 2025, a significant deterioration from a net income of $1,603,116 in the prior year period.
• Investment held in the Trust Account decreased dramatically to $8,315,560 as of June 30, 2025, from $75,794,241 as of December 31, 2024, primarily due to substantial shareholder redemptions.
• Ordinary shares subject to possible redemption fell from 6,900,000 shares at $10.98 per share ($75,794,241) on December 31, 2024, to 744,473 shares at $11.17 per share ($8,315,560) on June 30, 2025.
• Cash and cash equivalents declined to $17,556 as of June 30, 2025, from $103,774 as of December 31, 2024.
• A working capital deficit of $1,938,476 was reported as of June 30, 2025, compared to a deficit of $799,056 as of December 31, 2024.
• The company entered into a Prepaid Forward Purchase Agreement (FPA) on January 13, 2025, resulting in a $1,929,656 loss on issuance of FPA liability for the six months ended June 30, 2025, partially offset by a $1,123,154 gain from changes in fair value of FPA liability.
• The business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. (Qianzhi), agreed upon on January 18, 2024, remains pending regulatory approvals.
• Multiple Nasdaq delisting notices were received in July 2025 for failing to meet listing standards, including minimum publicly held shares, market value of listed securities, and total shareholders, leading to a trading halt.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, including a significant net loss, near-depleted trust account due to massive redemptions, and a substantial working capital deficit. The multiple Nasdaq delisting notices and trading halt indicate imminent failure as a public entity. While a business combination is pending, the company's ability to complete it and continue as a going concern is highly uncertain, making the outlook extremely negative.

Positives

• Successfully secured multiple extensions for the business combination period, most recently until December 14, 2025.
• Shareholders approved the business combination with Qianzhi on January 14, 2025.
• Management expects to obtain additional funds from related parties to address working capital deficit and continue operations.

Negatives

• Significant net loss of $1,289,691 for the six months ended June 30, 2025, compared to a net income in the prior year.
• Massive redemptions by public shareholders have depleted the Trust Account from over $75 million to approximately $8.3 million.
• Working capital deficit increased to $1,938,476, raising substantial doubt about the company's ability to continue as a going concern.
• Received multiple Nasdaq delisting notices for non-compliance with listing rules (publicly held shares, market value, total shareholders), leading to a trading halt.
• Identified a material weakness in internal control over financial reporting due to a lack of qualified SEC reporting professional.
• Incurred a significant loss on the issuance of FPA liability ($1,929,656).

Risks

• Substantial doubt about the ability to continue as a going concern due to low cash, working capital deficit, and the need to complete a business combination.
• Risk of delisting from Nasdaq due to non-compliance with multiple listing rules (minimum publicly held shares, market value of listed securities, market value of publicly held shares, and total shareholders).
• Failure to complete the business combination within the extended Combination Period (until December 14, 2025) would lead to liquidation and dissolution.
• Reliance on related parties for additional funding to cover working capital deficiencies and transaction costs.
• Material weakness in internal control over financial reporting due to a lack of qualified SEC reporting professional, which could affect financial reporting accuracy.
• Uncertainty regarding regulatory approvals for the proposed business combination with Qianzhi.

Future Outlook

The company aims to complete its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. by the extended deadline of December 14, 2025. Management expects to obtain additional funds from related parties to address working capital needs and continue operations, despite significant doubt about its ability to continue as a going concern. The company also intends to appeal Nasdaq's delisting determination and regain compliance with listing rules.

Management Comments

• "Management believes that these conditions [low cash, working capital deficit, need to complete Business Combination] raise substantial doubt about the Company's ability to continue as a going concern."
• "Management expects to obtain additional funds from related parties to provide the additional working capital necessary to carry out its objective to consummate a business combination."
• "Management intends to continue implement remediation steps to improve our disclosure controls and procedures and our internal control over financial reporting. Specifically, we intend to expand and improve our review process for complex securities and related accounting standards."
• "Management believes that the financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, result of operations and cash flows for the periods presented."

Industry Context

The filing highlights the inherent challenges faced by Special Purpose Acquisition Companies (SPACs) in the current market environment, particularly regarding shareholder redemptions and the pressure to complete a business combination within a defined timeframe. The significant redemptions experienced by Bowen Acquisition Corp. are indicative of a broader trend where SPACs struggle to retain investor capital, especially as deadlines approach and market sentiment shifts. The company's pursuit of a business combination with a biotechnology company in China (Shenzhen Qianzhi) suggests a focus on the life sciences or technology sectors, which have seen varying levels of SPAC activity. The Nasdaq delisting notices underscore the increased scrutiny and stricter compliance requirements for SPACs post-IPO, reflecting a more challenging regulatory and market landscape compared to the SPAC boom years.

Comparison to Industry Standards

• The redemption rate, which has reduced the Trust Account from $69.69 million to $8.3 million (a reduction of over 88%), is significantly higher than the average SPAC redemption rates observed in 2023-2024, which typically ranged from 50-70% for deals that closed. This high redemption rate is comparable to some of the most challenged SPACs that failed to complete deals or saw their trust accounts nearly fully depleted.
• The company's current cash balance of $17,556 and working capital deficit of $1,938,476 are extremely low for a public company, especially one attempting a business combination, indicating severe liquidity constraints compared to industry peers that typically maintain higher cash reserves or secure substantial PIPE (Private Investment in Public Equity) financing.
• The multiple Nasdaq listing deficiencies (public float, market value, shareholder count) are severe and indicate a failure to meet basic public company requirements, placing it among the most distressed SPACs that face imminent delisting, unlike many peers that might only have one or two minor compliance issues.
• The ongoing reliance on related party loans for working capital, without clear repayment terms, is a common but often concerning characteristic of distressed SPACs, contrasting with more robust SPACs that secure third-party financing or have sufficient trust funds.

Corporate Governance

Related Party Transactions

• Promissory Note: On October 14, 2024, EarlyBirdCapital, Inc. (EBC) loaned the Company $500,000, deposited into the Trust Account for an extension. The loan is non-interest bearing and repayable upon business combination consummation.
• Founder Shares Transfer: In connection with the loan, one of the Sponsors transferred 30,000 Founder Shares to EBC, valued at approximately $209,442, recorded as a debt discount and amortized as interest expense.
• Due to Related Party: As of June 30, 2025, $172,020 was owed to related parties for accrued expenses, including $150,000 for administration fees and $22,020 for accounting and other service fees.
• Accounting Service Agreement: The company pays TenX Global Capital, a related party, a fixed quarterly rate of $5,250 for accounting preparation and financial statement services.
• Administration Fee: An affiliate of the Sponsors charges up to $10,000 per month for office, utilities, and personnel use until the business combination closes.
• Business Combination Transaction Cost: Shenzhen Qianzhi (the target company) agreed to be responsible for all expenses incurred by the company in connection with the business combination. For the six months ended June 30, 2025, $422,386 of costs were incurred, with $384,212 reimbursed by Qianzhi.

Stakeholder Impact

• Shareholders: Public shareholders have experienced significant redemptions, drastically reducing their ownership and the trust account value. Remaining shareholders face high risk of delisting and potential liquidation if the business combination fails. The trading halt further restricts liquidity.
• Sponsors/Related Parties: Continue to provide financial support through loans and cover expenses, indicating ongoing commitment but also exposure to the company's financial distress.
• Target Company (Qianzhi): The pending business combination is critical for Qianzhi to become a public entity via this SPAC. Delays and the SPAC's financial/listing issues pose a significant risk to the completion of this transaction.
• Employees/Management: The going concern uncertainty and potential delisting create job insecurity and pressure to complete the business combination.
• Creditors: Related party creditors face uncertainty regarding repayment of loans if the business combination does not close.

Next Steps

• Complete the business combination with Shenzhen Qianzhi BioTechnology Co. Ltd., pending regulatory approvals, by December 14, 2025.
• Obtain additional funds from related parties to address working capital deficiencies and finance transaction costs.
• Submit a plan to Nasdaq by August 25, 2025, to regain compliance with listing rules.
• Appeal Nasdaq's delisting determination to a Nasdaq Hearings Panel by July 22, 2025, and request a stay of the trading suspension.
• Implement remediation steps to improve disclosure controls and procedures and internal control over financial reporting, including expanding review processes and potentially adding staff.

Key Dates

Recommendation

The company is in severe distress, evidenced by a substantial net loss, a near-depleted trust account due to massive redemptions, and a significant working capital deficit. The multiple Nasdaq delisting notices and the subsequent trading halt indicate a high probability of the company ceasing to be a publicly traded entity. While a business combination is pending, the company's ability to complete it and continue as a going concern is highly uncertain. The risks of further capital erosion, illiquidity, and potential liquidation are extremely high, making the stock an exceptionally poor investment.

Keywords

SPAC, Special Purpose Acquisition Company, Business Combination, Qianzhi, Nasdaq Delisting, Going Concern, Shareholder Redemptions, Trust Account, Forward Purchase Agreement, Financial Reporting, SEC Filing, Quarterly Report